Skip to main content
SpringerLink
Log in

Facilitating Adherence to Highly Active Antiretroviral Therapy in Children with HIV Infection

What Are the Issues and What Can Be Done?

  • Current Opinion
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Treatment of HIV infection with highly active antiretroviral therapy (HAART) requires sustained adherence to treatment to maintain efficacy. In pediatric patients, adherence to HAART represents a significant challenge for treated children and for their caregivers and healthcare providers.

Many factors can affect adherence to HAART including: (i) factors related to the patient and his/her family; (ii) factors related to the drug/medication; and (iii) factors related to the healthcare system. Different strategies can be employed to tackle the specific obstacles identified in these three groups, and thus to facilitate adherence.

Among the key interventions centered on the patient and his/her family are the tailoring of the HAART regimen to the daily activities of the child and his/her family, and the implementation of an intensive education program on adherence for the child and the caregiver, prior to starting the treatment. Specific medication-related problems (depending on drug pharmacokinetic and pharmacodynamic properties, taste and palatability, food interactions, etc.) exist; such problems can not be solved solely by clinicians or by families. Greater commitment of the pharmaceutical industry is needed, and innovative solutions have to be identified by clinicians in partnership with drug manufacturers.

Furthermore, the development of an ‘adherence strategy/program’ can be recommended to all institutions working in pediatric HIV infection. Most of the necessary interventions to be included in such progams can be easily implemented, but they require trained and committed staff (and institutions), and time to be spent with patients and their caregivers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI

Similar content being viewed by others

References

  1. Sharland M, Blanche S, Castelli G, et al. PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med 2002 Jul; 3(3): 215–26

    Article  PubMed  CAS  Google Scholar 

  2. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection: National Resource Center at the Francois-Xavier Bagnoud Center, UMDNJ. The Health Resources and Services Administration (HRSA), and The National Institutes of Health (NIH), March 24, 2005 [online]. Available from URL: http://AIDSinfo.nih.gov [Accessed 2005 Apr 10]

    Google Scholar 

  3. Hogg RS, Ealt KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279: 450–4

    Article  PubMed  CAS  Google Scholar 

  4. Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatients Study Investigators. N Engl J Med 1998; 338: 853–60

    Article  PubMed  Google Scholar 

  5. Watson DC, Farley JJ. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 1999 Aug; 18: 682–9

    Article  PubMed  CAS  Google Scholar 

  6. de Martino M, Tovo PA, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. JAMA 2000; 284: 190–7

    Article  PubMed  Google Scholar 

  7. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, April 7, 2005 [online]. Available from URL: http://AIDSinfo.nih.gov [Accessed 2005 Apr 10]

  8. Fätenheuer G, Theisen A, Rockstroh J, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997; 11: 113–6F

    Article  Google Scholar 

  9. Descamps D, Flandre P, Calvez V, et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA 2000; 283: 205–11

    Article  PubMed  CAS  Google Scholar 

  10. Press N, Tyndall MW, Wood E, et al. Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr 2002 Dec; 31Suppl. 3: 112–7S

    Article  Google Scholar 

  11. World Health Organization. Human immunodeficiency virus and acquired immunodeficiency syndrome. Chapter 12. In: World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization, 2003: 117–28

    Google Scholar 

  12. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection [published erratum appears in Ann Intern Med 2002 Feb; 136: 253]. Ann Intern Med 2000 Jul; 133: 21–30

    PubMed  CAS  Google Scholar 

  13. Sabate E. WHO Adherence Meeting Report. Geneva: World Health Organization, 2001

    Google Scholar 

  14. Haynes RB. Determinants of compliance: the disease and the mechanics of treatment. Baltimore (MD): Johns Hopkins University Press, 1979

    Google Scholar 

  15. Rand CS. Measuring adherence with therapy for chronic diseases: implications for the treatment of heterozygous familial hypercholesterolemia. Am J Cardiol 1993 Sep; 72(10): 68–74D

    Article  Google Scholar 

  16. World Health Organization. Defining adherence. Chapter 1. In: World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization, 2003: 17–9

    Google Scholar 

  17. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000; 30Suppl. 2: 171–6S

    Article  Google Scholar 

  18. Reddington C, Cohen J, Baldillo A, et al. Adherence to medication regimens among children with human immunodeficiency virus infection. Pediatr Infect Dis J 2000 Dec; 19: 1148–53

    Article  PubMed  CAS  Google Scholar 

  19. Wedekink CA, Pugatch D. Lipodystrophy syndrome in children infected with human immunodeficiency virus. Pharmacotherapy 2001; 21: 861–6

    Article  Google Scholar 

  20. Byrne M, Honig J, Jurgrau A, et al. Achieving adherence with antiretroviral medications for pediatric HIV disease. AIDS Read 2002 Apr; 12(4): 151–4, 161-4

    PubMed  Google Scholar 

  21. Ferris MG, Kline MW. Editorial comment: challenges to pediatric adherence to antiretroviral medications. AIDS Read 2002 Apr; 12(4): 162–3

    PubMed  Google Scholar 

  22. Thorne C, Newell ML, Botet FA, et al. Older children and adolescents surviving with vertically acquired HIV infection. J Acquir Immune Defic Syndr 2002 Apr; 29(4): 396–401

    PubMed  Google Scholar 

  23. van Rossum AM, Bergshoeff AS, Fraaij PL, et al. Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002 Aug; 21(8): 743–7

    Article  PubMed  Google Scholar 

  24. Demas PA, Webber MP, Schoenbaum EE, et al. Maternal adherence to the zidovudine regimen for HIV-exposed infants to prevent HIV infection: a preliminary study. Pediatrics 2002 Sep; 110(3): e35

    Article  PubMed  Google Scholar 

  25. Gibb DM, Goodall RL, Giacomet V, et al. Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial. Pediatr Infect Dis J 2003 Jan; 22(1): 56–62

    Article  PubMed  Google Scholar 

  26. Steele RG, Grauer D. Adherence to antiretroviral therapy for pediatric HIV infection: review of literature and recommendations for research. Clin Child Fam Psychol Rev 2003 Mar; 6(1): 17–30

    Article  PubMed  Google Scholar 

  27. King JR, Acosta EP, Chadwick E, et al. Evaluation of multiple drug therapy in human immunodeficiency virus-infected pediatric patients. Pediatr Infect Dis J 2003 Mar; 22(3): 239–44

    PubMed  Google Scholar 

  28. Brackis-Cott E, Mellins CA, Abrams E, et al. Pediatric HIV medication adherence: the views of medical providers from two primary care programs. J Pediatr Health Care 2003; 17(5): 252–60

    Article  PubMed  Google Scholar 

  29. Giacomet V, Albano F, Starace F, et al. Adherence to antiretroviral therapy and its determinants in children with human immunodeficiency virus infection: a multicentre, national study. Acta Paediatr 2003 Dec; 92(12): 1398–402

    Article  PubMed  CAS  Google Scholar 

  30. Mellins CA, Brackis-Cott E, Dolezal C, et al. The role of psychosocial and family factors in adherence to antiretroviral treatment in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2004 Nov; 23(11): 1035–41

    Article  PubMed  Google Scholar 

  31. Lwin R, Melvin D. Paediatric HIV infection. J Child Psychol Psychiatry 2001 May; 42(4): 427–38

    Article  PubMed  CAS  Google Scholar 

  32. Gavin PJ, Yogev R. The role of protease inhibitor therapy in children with HIV infection. Paediatr Drugs 2002; 4(9): 581–607

    PubMed  Google Scholar 

  33. Steele RG, Anderson B, Rindel B, et al. Adherence to antiretroviral therapy among HIV-positive children: examination of the role of caregiver health beliefs. AIDS Care 2001 Oct; 13(5): 617–29

    Article  PubMed  CAS  Google Scholar 

  34. Verweel G, van Rossum AM, Hartwig NG, et al. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Pediatrics 2002 Feb; 109(2): e25

    Article  PubMed  Google Scholar 

  35. Murphy DA, Wilson CM, Durako SJ, et al. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care 2001 Feb; 13: 27–40

    Article  PubMed  CAS  Google Scholar 

  36. Temple ME, Koranyi KI, Nahata MC. The safety and antiviral effect of protease inhibitors in children. Pharmacotherapy 2001 Mar; 21: 287–94

    Article  PubMed  CAS  Google Scholar 

  37. Ledlie SW. The psychosocial issues of children with perinatally acquired HIV disease becoming adolescents: a growing challenge for providers. AIDS Patient Care STDS 2001 May; 15(5): 231–6

    Article  PubMed  CAS  Google Scholar 

  38. Pontali E, Feasi M, Toscanini F, et al. Adherence to combination antiretroviral treatment in children. HIV Clin Trials 2001 Nov-Dec; 2(6): 466–73

    Article  PubMed  CAS  Google Scholar 

  39. Van Dyke RB, Lee S, Johnson GM, et al. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics 2002 Apr; 109(4): e61

    Article  PubMed  Google Scholar 

  40. Dolezal C, Mellins C, Brackis-Cott E, et al. The reliability of reports of medical adherence from children with HIV and their adult caregivers. J Pediatr Psychol 2003 Jul-Aug; 28(5): 355–61

    Article  PubMed  Google Scholar 

  41. King JR, Kimberlin DW, Aldrovandi GM, et al. Antiretroviral pharmacokinetics in the paediatric population: a review. Clin Pharmacokinet 2002; 41(14): 1115–33

    Article  PubMed  CAS  Google Scholar 

  42. Leonard EG, McComsey GA. Metabolic complications of antiretroviral therapy in children. Pediatr Infect Dis J 2003 Jan; 22(1): 77–84

    Article  PubMed  Google Scholar 

  43. Goode M, McMaugh A, Crisp J, et al. Adherence issues in children and adolescents receiving highly active antiretroviral therapy. AIDS Care 2003 Jun; 15(3): 403–8

    Article  PubMed  CAS  Google Scholar 

  44. Manfredi R, Chiodo F. Four-drug salvage antiretroviral treatment including nelfinavir and efavirenz in highly treated children with congenital HIV disease. Int J STD AIDS 2000 Feb; 11(2): 132–3

    PubMed  CAS  Google Scholar 

  45. United Nations Children’s Fund, The Joint United Nations Programme on HIV/AIDS, World Health Organization, Médecins Sans Frontières. Sources and prices of selected medicines and diagnostics for people living with HIV/AIDS. Geneva: World Health Organization, 2003

    Google Scholar 

  46. Byakika-Tusiime J, Oyugi JH, Tumwikirize WA, et al. Ability to purchase and secure stable therapy are significant predictors of non-adherence to antiretroviral therapy in Kampala, Uganda [abstract no. 170]. Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; 2003 Feb 10–14; Boston

  47. Daar ES, Cohen C, Remien R, et al. Improving adherence to antiretroviral therapy. AIDS Read 2003; 13(2): 81–90

    PubMed  Google Scholar 

  48. Katko E, Johnson GM, Fowler SL, et al. Assessment of adherence with medications in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2001 Dec; 20(12): 1174–6

    Article  PubMed  CAS  Google Scholar 

  49. Bale H. How the pharmaceutical industry can help in enhancing adherence to long-term therapies. Annex II. In: World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization, 2003: 178–9

    Google Scholar 

  50. Roberts GM, Wheeler JG, Tucker NC, et al. Nonadherence with pediatric human immunodeficiency virus therapy as medical neglect. Pediatrics 2004; 114(3): e346–53

    Article  PubMed  Google Scholar 

  51. Berrien VM, Salazar JC, Reynolds E, et al. Adherence to antiretroviral therapy in HIV-infected pediatric patients improves with home-based intensive nursing intervention. AIDS Patient Care STDS 2004 Jun; 18(6): 355–63

    Article  PubMed  Google Scholar 

  52. Marhefka SL, Farley JJ, Rodrigue JR, et al. Clinical assessment of medication adherence among HIV-infected children: examination of the Treatment Interview Protocol (TIP). AIDS Care 2004 Apr; 16(3): 323–38

    Article  PubMed  CAS  Google Scholar 

  53. Mendoza C, Ramos JT, Ciria L, et al. Efficacy and safety of stavudine plus didanosine in asymptomatic HIV-infected children with plasma HIV RNA below 50,000 copies per milliliter. HIV Clin Trials 2002 Jan-Feb; 3(1): 9–16

    Article  PubMed  Google Scholar 

  54. McComsey G, Bhumbra N, Ma JF, et al. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study. Pediatrics 2003 Mar; 111(3): e275–81

    Article  PubMed  Google Scholar 

  55. van Heeswijk RPG, Veldkamp AI, Mulder JW, et al. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antivir Ther 2002 Dec; 6(4): 201–29

    Google Scholar 

  56. Handforth J, Sharland M. Triple nucleoside reverse transcriptase inhibitor therapy in children. Pediatr Drugs 2004; 6(3): 147–59

    Article  Google Scholar 

  57. Cohen J, Reddington C, Jacobs D, et al. School-related issues among HIV-infected children. Pediatrics 1997 Jul; 100: e8

    Article  PubMed  CAS  Google Scholar 

  58. Hoffmann F, Notheis G, Wintergerst U, et al. Comparison of ritonavir plus saquinavir and nelfinavir plus saquinavir-containing regimens as salvage therapy in children with human immunodeficiency virus type 1 infection. Pediatr Infect Dis J 2000 Jan; 19(1): 47–51

    Article  PubMed  CAS  Google Scholar 

  59. Chadwick EG, Rodman JH, Samson P, et al. Antiviral activity, tolerance and pharmacokinetics of indinavir with two doses of ritonavir as salvage therapy in children [abstract no. 875]. Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; 2003 Feb 10–14; Boston

  60. Aarnoutse R, Schapiro J, Boucher C, et al. Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs? Drugs 2003; 63(8): 741–53

    Article  PubMed  CAS  Google Scholar 

  61. Albano F, Spagnuolo MI, Berni Canani R, et al. Adherence to antiretroviral therapy in HIV-infected children in Italy. AIDS Care 1999 Dec; 11: 711–4

    Article  PubMed  CAS  Google Scholar 

  62. Farmer P, Léandre F, Mukherjee J, et al. ARV community-based treatment of advanced HIV disease: introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy). Bull World Health Organ 2001; 79(12): 1145–51

    PubMed  CAS  Google Scholar 

  63. Gigliotti F, Murante BL, Weinberg GA. Short course directly observed therapy to monitor compliance with antiretroviral therapy in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2001 Jul; 20(7): 716–8

    Article  PubMed  CAS  Google Scholar 

  64. Farley J, Hines S, Musk A, et al. Assessment of adherence to antiviral therapy in HIV-infected children using the medication event monitoring system, pharmacy refill, provider assessment, caregiver self-report, and appointment keeping. J Acquir Immune Defic Syndr 2003 Jun; 33(2): 211–8

    Article  PubMed  Google Scholar 

  65. Shingadia D, Viani RM, Yogev R, et al. Gastrostomy tube insertion for improvement of adherence to highly active antiretroviral therapy in pediatric patients with human immunodeficiency virus. Pediatrics 2000 Jun; 105(6): e80

    Article  PubMed  CAS  Google Scholar 

  66. Temple ME, Koranyi KI, Nahata MC. Gastrostomy tube placement in nonadherent HIV-infected children. Ann Pharmacother 2001 Apr; 35(4): 414–8

    Article  PubMed  CAS  Google Scholar 

  67. Reinstein J. How better labels and package inserts could help people increase their adherence to therapies. Annex II. In: World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization, 2003

    Google Scholar 

  68. Mitty JA, Stone VE, Sands M, et al. Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress. Clin Infect Dis 2002; 34: 984–90

    Article  PubMed  Google Scholar 

  69. van Rossum AM, Fraaij PL, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis 2002 Feb; 2(2): 93–102

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

No sources of funding were used to assist in the preparation of this review. The author has no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, Galliera Hospital, Genoa, Italy

    Emanuele Pontali

Authors
  1. Emanuele Pontali
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emanuele Pontali.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pontali, E. Facilitating Adherence to Highly Active Antiretroviral Therapy in Children with HIV Infection. Pediatr-Drugs 7, 137–149 (2005). https://doi.org/10.2165/00148581-200507030-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00148581-200507030-00001

Keywords

Search

Navigation